| Aug 30 |
HUTCHMED pulls regulatory submission for Takeda-partnered cancer drug in China
|
| Aug 28 |
Takeda Pharmaceutical Company Limited (TAK): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
|
| Aug 8 |
Takeda’s ADZYNMA gains EU approval for cTTP treatment
|
| Aug 7 |
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
|
| Aug 7 |
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
|
| Aug 6 |
Japan Fund That Beat 92% of Peers in 2024 Touts Seven & I, Orix
|
| Aug 5 |
Japan’s Selloff Sank Global Markets. Why This Fund Manager Is Still Bullish.
|
| Aug 2 |
Update: Market Chatter: Takeda Pharmaceutical to Eliminate 1,000 US Jobs
|
| Aug 2 |
Takeda confirms plans to cut over 1,000 U.S. jobs: report
|
| Aug 2 |
Takeda Pharmaceutical Company Limited (TAK) Q1 2025 Earnings Call Transcript
|
